The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Propensity score analysis: Frontline therapy with high-dose (HD) imatinib vs. 2nd generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in chronic phase.
 
Koji Sasaki
No Relationships to Disclose
 
Hagop M. Kantarjian
Research Funding - Amgen (Inst); ARIAD (Inst); Bristol-Myers Squibb (Inst); Delta-Fly Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Elias Jabbour
No Relationships to Disclose
 
Farhad Ravandi
Research Funding - Bristol-Myers Squibb; Novartis
 
Koichi Takahashi
No Relationships to Disclose
 
Marina Konopleva
No Relationships to Disclose
 
Gautam Borthakur
No Relationships to Disclose
 
Guillermo Garcia-Manero
No Relationships to Disclose
 
William G. Wierda
No Relationships to Disclose
 
Naval Guastad Daver
No Relationships to Disclose
 
Preetesh Jain
No Relationships to Disclose
 
Sherry Pierce
No Relationships to Disclose
 
Mary Beth Rios
No Relationships to Disclose
 
Jorge E. Cortes
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva